Has Pfizer Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Pfizer (NYSE: PFE  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Pfizer.

Factor

What We Want to See

Actual

Pass or Fail?

Growth

5-Year Annual Revenue Growth > 15%

5.3%

Fail

 

1-Year Revenue Growth > 12%

(7.2%)

Fail

Margins

Gross Margin > 35%

80.7%

Pass

 

Net Margin > 15%

15.6%

Pass

Balance Sheet

Debt to Equity < 50%

48.3%

Pass

 

Current Ratio > 1.3

1.91

Pass

Opportunities

Return on Equity > 15%

10.7%

Fail

Valuation

Normalized P/E < 20

16.06

Pass

Dividends

Current Yield > 2%

3.6%

Pass

 

5-Year Dividend Growth > 10%

(5.4%)

Fail

       
 

Total Score

 

6 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Pfizer last year, the company held onto the point it gained between 2010 and 2011. The stock is up 25% in the past year, but the drugmaker faces a huge challenge that could threaten its score in years to come.

Pfizer has provided huge returns for investors over the years, thanks to its stable of blockbuster drugs. With major patent cliffs approaching for Merck (NYSE: MRK  ) , Eli Lilly (NYSE: LLY  ) , and especially Pfizer, investors had a lot of concerns about the ability of big pharma stocks to hold up, and responded by pushing valuations down to very low levels. Yet those lower bars set the stage for outperformance, which Pfizer and its peers have delivered soundly in recent months.

Still, the recent loss of patent protection for blockbuster drug Lipitor has had a decided impact on the company's revenue. In its most recent quarter, Pfizer saw revenue plunge 16%, with sales of Lipitor dropping 87% in the U.S. and 71% around the world. Despite attempts to sustain sales of generic Lipitor, the cheaper price means Pfizer will never see anything close to peak revenue from the drug again.

To restore the pipeline, Pfizer has dozens of drugs in development. In September, its chronic myelogenous leukemia drug bosutinib got approval as an orphan drug from the Food and Drug Administration. Pfizer's hoping to get a similar boost from tofacitinib, which it's targeting for rheumatoid arthritis. And despite a setback for potential blockbuster Eliquis when the FDA asked for more data in June, Pfizer and partner Bristol-Myers Squibb (NYSE: BMY  ) have resubmitted the requested information and are hoping for approval soon.

Pfizer remains committed to its core drug business, following the same path as Abbott Labs (NYSE: ABT  ) by reorganizing to get rid of peripheral units. While Abbott is moving toward splitting off its medical device business from its drug development segment, Pfizer sold its nutrition business to Nestle in April and expects to spin off its Zoetis animal-health unit in the first half of next year.

For Pfizer to improve, it needs to get its pipeline humming again to replace Lipitor's lost revenue. If it succeeds, then Pfizer has plenty of room to run toward perfection in the future.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

While you can certainly make huge gains in pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Click here to add Pfizer to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 05, 2012, at 11:15 AM, Njja wrote:

    In a simple one word answer NO!

    Pfizer has been a DOG for years. Lets look at the fact that the dividend yields less then BMY after Pfizer cut it in half in 2009.

    Over the years I have held a position in this DOG until I could no longer endure the pain!

    In short I would only recommend this stock to Obama since he has ruined our economy it would be a good investment for him.

  • Report this Comment On November 05, 2012, at 12:31 PM, rsinj wrote:

    Under prior management the previous reply is unquestionably true. A slew of large/questionable acquisitions, senior management that was out of touch with how to run a company like this, and the obvious end result a decade of watching the stock lose over 50% of its value.

    However, with new management comes change. Selling the stock now, or any time this year has been a mistake. The abyss has been visited and things are looking up going forward. Yes, there are still issues, but the new CEO is thinking better than Kindler ever did. Divestitures of non-core businesses makes sense, and as was seen earlier this year, bidders are paying a premium price for assets they are interested in.

    Pfizer cut the dividend in half to fund the Wyeth acquisition. If you had been a long term shareholder, surely you know this. Further, considering the economic and interest rate environment, the yield didn't make sense - it was what was supporting the stock price. Now with business on the right path, earnings will help move the stock in the right direction, and the historical dividend policy of annual increases will once again be seen.

    In short, you sold at the wrong time. The better approach was to be acquiring continually on the way down during the past few years - through a DRIP, or other ways of making periodic purchases.

    Long term, Pfizer will be fine and do well.

  • Report this Comment On November 05, 2012, at 5:48 PM, Njja wrote:

    There are far to many well run companies for today's investor to consider investing in this DOG. It's nice that it has new leadership, and kind of you to point out the bad decisions which resulted in the 50% reduction in dividends and reduced stock price.

    However the reason American Motors, Nash and Hudson no longer make cars does not encourage us to ask for their return.

    If you like this particular field buy Merck, BMY, JNJ.

    If you are considering Pfizer try and invest with someone else's money, make it someone you don't like.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2095372, ~/Articles/ArticleHandler.aspx, 11/27/2014 8:39:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement